Vir Biotechnology Inc VIR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:42 PM EDT
9.55quote price arrow down-0.38 (-3.78%)
Volume
243,542
52 week range
7.61 - 27.48
Loading...
  • Open9.81
  • Day High9.89
  • Day Low9.49
  • Prev Close9.93
  • 52 Week High27.48
  • 52 Week High Date06/13/23
  • 52 Week Low7.61
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap1.30B
  • Shares Out136.06M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.48
  • YTD % Change-5.32

KEY STATS

  • Open9.81
  • Day High9.89
  • Day Low9.49
  • Prev Close9.93
  • 52 Week High27.48
  • 52 Week High Date06/13/23
  • 52 Week Low7.61
  • 52 Week Low Date04/25/24
  • Market Cap1.30B
  • Shares Out136.06M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.48
  • YTD % Change-5.32

RATIOS/PROFITABILITY

  • EPS (TTM)-4.01
  • P/E (TTM)-2.38
  • Fwd P/E (NTM)-2.41
  • EBITDA (TTM)-589.685M
  • ROE (TTM)-30.67%
  • Revenue (TTM)79.599M
  • Gross Margin (TTM)98.85%
  • Net Margin (TTM)-677.69%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vir Biotechnology Inc

 

Profile

MORE
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19...
Vicki Sato Ph.D.
Independent Chairman of the Board
Marianne De Backer Ph.D.
Chief Executive Officer, Director
Ann Hanly Ph.D.
Executive Vice President, Chief Technology Officer
Jennifer Towne Ph.D.
Executive Vice President, Chief Scientific Officer
Jeffrey Calcagno M.D.
Executive Vice President and Chief Business Officer
Address
1800 OWENS STREET, SUITE 900
San Francisco, CA
94158
United States

Top Peers

SYMBOLLASTCHG%CHG
RCUS
Arcus Biosciences Inc
15.29-0.27-1.74%
PRTA
Prothena Corporation PLC
23.10-0.44-1.87%
LGND
Ligand Pharmaceuticals Inc
80.61+7.39+10.09%
TARS
Tarsus Pharmaceuticals Inc
36.67-1.36-3.58%
FDMT
4D Molecular Therapeutics Inc
26.15-0.65-2.43%